Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study

Jiangtao Cheng(Zhengzhou University), Jin‐Ji Yang(Guangdong General Hospital), Hai‐Yan Tu(Jiangnan University), Shuyin Chen(Guangdong Medical College), Xu‐Chao Zhang(Guangdong Academy of Medical Sciences), Qing Zhou(Jiangnan University), Zhen Wang(Guangdong Academy of Medical Sciences), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Jian Su(Jiangsu Province Blood Center), Hua‐Jun Chen(Fujian Medical University), Xuan Lin(Beijing Technology and Business University), Shiling Zhang(China National Petroleum Corporation (China)), Yihui Yao(Guangdong Academy of Medical Sciences), Jianxing Xiang(Burning Rock Biotech (China)), Zhi Hai Xie(Guangdong Academy of Medical Sciences), Hong‐Hong Yan(Sun Yat-sen University), Yu-Er Gao(Guangdong Academy of Medical Sciences), Analyn Lizaso(Burning Rock Biotech (China))
Lung Cancer
October 20, 2020
10.1016/j.lungcan.2020.10.010
Cited by 9

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k